缬沙坦联合叶酸治疗老年高血压肾病的临床效果及相关炎性因子改变观察分析-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

缬沙坦联合叶酸治疗老年高血压肾病的临床效果及相关炎性因子改变观察分析

Clinical effect of valsartan combined with folic acid in the treatment of elderly hypertensive nephropathy and the changes of related inflammatory factors

ES评分 0 浏览量：715 下载量：0

全文阅读下载引用收藏

DOI	10.12208/j.ijcr.20220335
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2022, 6(7)
作者	李晓庆*,高桂娟,孙春艳,
作者单位	北京市朝阳区左家庄社区卫生服务中心北京市朝阳区 ;
摘要	分析老年高血压肾病患者运用缬沙坦联合叶酸治疗的临床有效性及相关炎性因子改变。方法本文病例筛选2020年2月—2022年2月期间我院全科门诊诊治的老年高血压肾病患者48例，根据随机数字表分组方式将所纳入的患者分成对照与观察两组各24例，对照组患者治疗运用单独缬沙坦；观察组患者采取缬沙坦与叶酸联合方案治疗，将最终两组治疗方案获得的临床效果进行对比。结果治疗后两组各项指标结果比较显示，观察组患者的血压水平和炎性因子指标同对照组相比均得到显著改善，且观察组患者治疗后的肾功能损伤程度与对照组相比无明显进展，组间指标对比差异统计学意义存在（P＜0.05）；最终观察组患者取得的治疗总有效率也显著高于对照组，两组指标差值有统计学意义（P＜0.05）；观察组患者的生活质量与对照组相比显著提高，组间数据结果比较差值存在统计学意义（P＜0.05）。结论运用缬沙坦联合叶酸治疗老年高血压肾病，能够进一步提升临床治疗效果，确保患者血压保持的平稳状态，减轻患者肾功能损伤程度，降低疾病对患者健康及生活造成的影响。
Abstract	Objective: To analyze the clinical efficacy of valsartan combined with folic acid in elderly patients with hypertensive nephropathy and the changes of related inflammatory factors. Methods:48 elderly patients with hypertensive nephropathy diagnosed and treated in the general outpatient department of our hospital from February 2020 to February 2022 were selected. According to the grouping method of random number table, the included patients were divided into control group and observation group, with 24 cases in each group. The patients in the control group were treated with valsartan alone; The patients in the observation group were treated with the combination of valsartan and folic acid, and the clinical effects of the two groups were compared. Results:after treatment, the results of the two groups showed that the blood pressure level and inflammatory factors in the observation group were significantly improved compared with those in the control group, and there was no significant progress in the degree of renal function injury in the observation group compared with those in the control group. There was a statistically significant difference in the indexes between the two groups (P<0.05); The total effective rate of the observation group was also significantly higher than that of the control group, and the difference between the two groups was statistically significant (P<0.05); Compared with the control group, the quality of life of the patients in the observation group was significantly improved, and the difference of data results between the groups was statistically significant (P<0.05). Conclusion: Valsartan combined with folic acid in the treatment of elderly hypertensive nephropathy can further improve the clinical treatment effect, ensure that the blood pressure of patients remains stable, reduce the degree of renal function damage, and reduce the impact of the disease on the health and life of patients.
关键词	老年高血压；肾病；缬沙坦；叶酸；效果分析
KeyWord	Senile Hypertension; Nephrosis; Valsartan; Folic Acid; Effect Analysis
基金项目
页码	150-153

参考文献
相关文献

[1] 张磊, 曹微, 田加坤,等.前列地尔联合依那普利叶酸治疗高血压肾病患者的临床研究[J]. 中国临床药理学杂志,2020,36(18):4.

[2] 王克坤.缬沙坦联合叶酸治疗老年高血压肾病的治疗效果和作用机制探讨[J].心血管病防治知识,2020, 10(36): 9-11.

[3] 王娅敏, 刘智美, 苟玉竹,等.依那普利联合缬沙坦治疗糖尿病肾病伴高血压对血压及血清炎症因子的影响[J].西部医学,2021,33(8):4.

[4] 何培燕,林超师,林南生.厄贝沙坦联合叶酸治疗中老年高血压肾病的临床疗效探讨[J].中国现代药物应用,2020,14(9):125-127.

[5] 黄小平,郑德进,王高生.缬沙坦治疗高血压伴心力衰竭的疗效及其对患者血清hs-CRP水平、生活质量的影响[J].海南医学,2018,29(14):2033-2035.

引用本文

李晓庆*,高桂娟,孙春艳. 缬沙坦联合叶酸治疗老年高血压肾病的临床效果及相关炎性因子改变观察分析 [J]. 国际临床研究杂志. 2022; 6; (7). 150 - 153.

文献评论

相关学者

相关机构